

Honolulu, Hawaii - 2008 (N=79)

Figure A. Age of GISP participants, in years, 2008




Figure B. Race/ethnicity of GISP participants, 2008




Figure C. Percentage of GISP participants identifying as men who have sex with men, 1999-2008





Figure D. Reason for visit among GISP participants, 2008



Honolulu, Hawaii - 2008 (N=79)

Figure E. Previous episode of gonorrhea among GISP participants, 1991-2008

Data currently not available.

Figure F. Drugs used to treat gonorrhea among GISP participants, 2008




Figure G. Drugs used to treat *Chlamydia trachomatis* infection among GISP participants, 2008





Figure H. Resistance to penicillin, tetracycline, and ciprofloxacin among GISP isolates, 2008




Honolulu, Hawaii - 2008 (N=79)

Figure I. Decreased susceptibility to ceftriaxone among GISP isolates, 1990-2008

No isolates with decreased susceptibility to ceftriaxone have been identified at this clinic during this time period.


Note: Susceptibility to ceftriaxone first measured in 1987.

Figure J. Decreased susceptibility to cefixime among GISP isolates, 1992-2006




Note: Susceptibility to cefixime first measured in 1992. However, susceptibility testing for cefixime was discontinued in 2007 and 2008.

Figure K. Intermediate resistance and resistance to ciprofloxacin among GISP isolates, 1990-2008



Note: Susceptibility to ciprofloxacin first measured in 1990.

Figure L. Decreased susceptibility to azithromycin among GISP isolates, 1992-2008



Note: Susceptibility to azithromycin first measured in 1992. Decreased susceptibility to azithromycin is defined here as greater than or equal to 2.0 µg/ml. No CLSI criteria currently exist.